biostudies-literatureUnknown13Wan-Tong ZNational Natural Science Foundation of China<b>Background:</b> No effective medication is available for symptomatic bradyarrhythmia, particularly in low socioeconomic status (SES) population. <b>Objective:</b> To explore the safety and efficacy of Yuanjiang decoction, a traditional Chinese medicinal prescription, for symptomatic bradyarrhythmia on a compassionate-use basis. <b>Methods:</b> This compassionate-use study was conducted in Beijing, China between January 2019 and January 2020. Eligible participants were recruited and treated with Yuanjiang decoction (composed of 6 Chinese herbal medicines), 200 ml twice daily for 16 weeks. Analyses were done with the intention-to-treat (ITT) approach. The primary outcome measure was the proportion of participants who achieved a favorable treatment outcome at 16 weeks. <b>Results:</b> As oFrontiers in pharmacology764930https://www.ebi.ac.uk/biostudies/studies/S-EPMC9035522biostudies-literatureCompassionate Use of Yuanjiang Decoction, a Traditional Chinese Medicinal Prescription, for Symptomatic Bradyarrhythmia.PMC9035522Bao-Chen ZMiles PZhao LXu-Jie WWan-Tong ZYu-Fei WWei TRui GNing XWei-Liang WQiu-Yan LHao-Xiang LfalseCompassionate Use of Yuanjiang Decoction, a Traditional Chinese Medicinal Prescription, for Symptomatic Bradyarrhythmia.<b>Background:</b> No effective medication is available for symptomatic bradyarrhythmia, particularly in low socioeconomic status (SES) population. <b>Objective:</b> To explore the safety and efficacy of Yuanjiang decoction, a traditional Chinese medicinal prescription, for symptomatic bradyarrhythmia on a compassionate-use basis. <b>Methods:</b> This compassionate-use study was conducted in Beijing, China between January 2019 and January 2020. Eligible participants were recruited and treated with Yuanjiang decoction (composed of 6 Chinese herbal medicines), 200 ml twice daily for 16 weeks. Analyses were done with the intention-to-treat (ITT) approach. The primary outcome measure was the proportion of participants who achieved a favorable treatment outcome at 16 weeks. <b>Results:</b> As o2022-01-01T00:00:00Z20222025-04-21T16:47:09.495Z2025-04-21T16:47:09.495ZS-EPMC90355223547931510.3389/fphar.2022.764930